

## THE NOTITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Carlos R. Plata-Salaman et al.

Serial No. : 10/081,606

Art Unit: 1614

Filed

: February 21, 2002

Examiner: D.A. Jagoe

IN

For

: CARBAMATE COMPOUNDS USE

PREVENTING

OR

TREATING BIPOLAR DISORDERS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

FOR

January 5, 2006 (Date) Peter L. Herridge ssignee, or Registered Representative January 5, 2006 (Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## PETITION TO WITHDRAW PURSUANT TO 37 CFR 1.313(c)

Dear Sir:

Applicants, through their attorney, hereby petition for withdrawal of the above-referenced application from issuance. Please charge the appropriate fee pursuant to 37 CFR  $\delta$ 1.17(h) to Johnson & Johnson Deposit Account No. 10-07450/ORT1581/PLH.

01/10/2006 RMEBRAHT 00000102 100750 10081606 130.00 DA 02 FC:1464

The issue fee for the above-identified application was paid on June 30, 2005.

The documents listed on Form PTO-1449 came to the Applicants' attorney's attention on December 8, 2005. Applicants received an Office Action from the Patent Office of the Russian Federation concerning the equivalent Russian case. The Russian Examiner had cited two articles which were characterized as describing a "close analog" of the claimed invention or describing the use of anticonvulsants to prevent the "depressing phase of BD". The references are both in Russian and English abstracts could not be found. Applicant is presently arranging for a translation of both references and they will be submitted as soon as available.

Applicants request continued examination of the application under 37 CFR  $\delta$  1.114 and authorize the payment of any fee pursuant to 37 CFR  $\delta$  1.117(e) to Johnson & Johnson Deposit Account No. 10-0750/ORT1581/PLH.

An Information Disclosure Statement is submitted herewith in accordance with 37 CFR  $\delta$  1.114(b).

٠. ١

Please withdraw the above-referenced application from issuance so that the Information Disclosure Statement may be considered in a Request for Continued Examination.

Respectfully submitted,

Peter L.

L. Herridg∉

January 5, 2006

Attorney for Applicants

Req. No. 42,658

Johnson & Johnson

One Johnson & Johnson Plaza

New Brunswick, NJ 08933

732-524-5352